Работы, цитирующие эту работу

Работ: 4

Работа: The Evolving Future of PCSK9 Inhibitors

1. Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?

   Aleksandr B. Shek, Rano B. Alieva, R. D. Kurbanov +3

   СтатьяLipoproteins and Cardiovascular HealthArchives of Medical Science - Atherosclerotic Diseases2019Цитирований: 0

   ABIABI:AkademIndex/openalex/2019.article.000163

2. Reinforcing Adherence to Lipid-lowering Therapy after an Acute Coronary Syndrome: A Pragmatic Randomized Controlled Trial

   Stefanos Zafeiropoulos, Ioannis T. Farmakis, Αναστάσιος Κάρτας +6

   ПрепринтLipoproteins and Cardiovascular HealthResearch Square2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.preprint.000048

3. Reinforcing Adherence to Lipid-lowering Therapy after an Acute Coronary Syndrome: A Pragmatic Randomized Controlled Trial

   Stefanos Zafeiropoulos, Ioannis T. Farmakis, George Giannakoulas +1

   ПрепринтLipoproteins and Cardiovascular HealthResearch Square2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.preprint.000099

4. Nanoparticle-Based PCSK9 Inhibition in Viral Infections: Evaluating Clinical Limitations and Advancing Therapeutic Strategies

   Moeen F. Dababneh, Bahjat Alhasso, Abdulkareem Shareef +10

   СтатьяLipoproteins and Cardiovascular HealthJournal of Pharmaceutical Innovation2026Цитирований: 0

   ABIABI:AkademIndex/openalex/2026.article.013240